Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Antiangiogenic drugs are used clinically for treatment of renal cell carcinoma (RCC) as a standard first-line treatment. Nevertheless, these agents primarily serve to stabilize disease, and resistance eventually develops concomitant with progression. Here, we implicate metabolic symbiosis between tu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cell Rep
Egile Nagusiak: Jiménez-Valerio, Gabriela, Martínez-Lozano, Mar, Bassani, Nicklas, Vidal, August, Ochoa-de-Olza, María, Suárez, Cristina, García-del-Muro, Xavier, Carles, Joan, Viñals, Francesc, Graupera, Mariona, Indraccolo, Stefano, Casanovas, Oriol
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cell Press 2016
Gaiak:
Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4870515/
https://ncbi.nlm.nih.gov/pubmed/27134180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.04.015
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak